|
RLMD Relmada Therapeutics Inc 1553643 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-19,051,956.00 |
| Balance Sheet |
|
Current Assets
|
$235,343,294.00 |
|
Assets
|
$235,362,794.00 |
|
Current Liabilities
|
$12,891,634.00 |
|
Liabilities
|
$16,630,217.00 |
|
Equity
|
$218,732,577.00 |
|
Shares Out
|
104890223.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-15,067,488.00 |
|
Investing Cash Flow
|
$-135,226,997.00 |
| Market Analysis |
Market Cap
|
$561,162,693.05 |
|
Price
|
$5.10 |
|
BVPS
|
2.09 |
|
PB
|
2.56 |
|
EPS
|
-0.22 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:27 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:23 |
|
| Apr |
May |
Jun |
| 2026-03-19 |
-0.27 |
|
|
2026-05-12 |
-0.22 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-07 |
-0.30 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-13 |
-0.30 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view RLMD documents filed with the SEC.
RLMD Filings
Clear
